MX2016009589A - Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes. - Google Patents
Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes.Info
- Publication number
- MX2016009589A MX2016009589A MX2016009589A MX2016009589A MX2016009589A MX 2016009589 A MX2016009589 A MX 2016009589A MX 2016009589 A MX2016009589 A MX 2016009589A MX 2016009589 A MX2016009589 A MX 2016009589A MX 2016009589 A MX2016009589 A MX 2016009589A
- Authority
- MX
- Mexico
- Prior art keywords
- aryl
- substituted pyrazolyl
- arylalkyl substituted
- antioxidant inflammation
- inflammation modulators
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000003226 pyrazolyl group Chemical group 0.000 title 1
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La solicitud actual se refiere a (a) compuestos de la Fórmula (I): (ver Fórmula) y sales de los mismos, en donde R1, R2, R3, R4, R5, R6, m, n, X e Y son como se define en la especificación; (b) composiciones que comprenden tales compuestos y sales; y (c) métodos de uso de tales compuestos, sales, y composiciones, particularmente útiles para el tratamiento y prevención de enfermedades tales como aquellas asociadas con tensión oxidante e inflamación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931291P | 2014-01-24 | 2014-01-24 | |
| PCT/US2015/012579 WO2015112792A1 (en) | 2014-01-24 | 2015-01-23 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009589A true MX2016009589A (es) | 2016-10-28 |
| MX372772B MX372772B (es) | 2020-06-29 |
Family
ID=52484552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009589A MX372772B (es) | 2014-01-24 | 2015-01-23 | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9464082B2 (es) |
| EP (1) | EP3097089B1 (es) |
| JP (1) | JP6530758B2 (es) |
| CN (1) | CN107074801B (es) |
| CA (1) | CA2936550C (es) |
| MX (1) | MX372772B (es) |
| TW (1) | TWI670263B (es) |
| WO (1) | WO2015112792A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| KR101735807B1 (ko) | 2008-04-18 | 2017-05-15 | 리타 파마슈티컬스 잉크. | Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제 |
| ME02926B (me) | 2012-04-27 | 2018-04-20 | Reata Pharmaceuticals Inc | 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| UY39092A (es) | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| US11059792B2 (en) * | 2015-02-12 | 2021-07-13 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| WO2018095953A1 (de) | 2016-11-23 | 2018-05-31 | Bayer Cropscience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel |
| TWI831738B (zh) * | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| BR112020025605A2 (pt) * | 2018-06-15 | 2021-03-23 | Reata Pharmaceuticals, Inc. | compostos de pirazol e imidazol para inibição de il-17 e rorgama |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| US20250025465A1 (en) * | 2021-11-17 | 2025-01-23 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| EP1438293A2 (en) * | 2001-09-19 | 2004-07-21 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| MY163031A (en) | 2010-04-12 | 2017-07-31 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
| HUE038046T2 (hu) * | 2010-12-17 | 2018-09-28 | Reata Pharmaceuticals Inc | Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok |
-
2015
- 2015-01-23 EP EP15705409.9A patent/EP3097089B1/en active Active
- 2015-01-23 US US14/604,129 patent/US9464082B2/en active Active
- 2015-01-23 TW TW104102426A patent/TWI670263B/zh active
- 2015-01-23 JP JP2016548158A patent/JP6530758B2/ja active Active
- 2015-01-23 WO PCT/US2015/012579 patent/WO2015112792A1/en not_active Ceased
- 2015-01-23 CN CN201580015069.4A patent/CN107074801B/zh active Active
- 2015-01-23 CA CA2936550A patent/CA2936550C/en active Active
- 2015-01-23 MX MX2016009589A patent/MX372772B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017503840A (ja) | 2017-02-02 |
| CA2936550C (en) | 2022-07-26 |
| MX372772B (es) | 2020-06-29 |
| WO2015112792A1 (en) | 2015-07-30 |
| JP6530758B2 (ja) | 2019-06-12 |
| US9464082B2 (en) | 2016-10-11 |
| TWI670263B (zh) | 2019-09-01 |
| CN107074801A (zh) | 2017-08-18 |
| EP3097089A1 (en) | 2016-11-30 |
| CN107074801B (zh) | 2021-11-05 |
| TW201605808A (zh) | 2016-02-16 |
| US20150225397A1 (en) | 2015-08-13 |
| EP3097089B1 (en) | 2021-02-24 |
| CA2936550A1 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016009589A (es) | Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes. | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CR20170573A (es) | Lactamas bicíclicas y métodos de uso de las mismas | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| UY36076A (es) | Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen. | |
| DOP2016000125A (es) | MODULADORES DE ROR GAMMA (RORy) | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
| GT201500190A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| UY36311A (es) | Indazoles sustituidos con bencilo | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CL2017000372A1 (es) | Composiciones novedosas, usos y métodos para hacerlas. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2017007377A (es) | Compuestos organicos. | |
| UY35305A (es) | Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap) | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| ECSP17010238A (es) | Compuestos novedosos de pirimidina sustituidos | |
| MX2017005044A (es) | Activador de canales de kcnq2-5. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: REATA PHARMACEUTICALS, INC. |
|
| FG | Grant or registration |